EVAXION BIOTECH AS
NASDAQ: EVAX (Evaxion A/S)
Last update: 2 days ago, 6:26PM6.21
-0.24 (-3.72%)
| Previous Close | 6.45 |
| Open | 6.41 |
| Volume | 70,755 |
| Avg. Volume (3M) | 1,630,773 |
| Market Cap | 51,792,736 |
| Price / Sales | 3.19 |
| Price / Book | 4.81 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Operating Margin (TTM) | -431.34% |
| Diluted EPS (TTM) | -12.00 |
| Quarterly Revenue Growth (YOY) | 67.10% |
| Total Debt/Equity (MRQ) | 837.11% |
| Current Ratio (MRQ) | 2.01 |
| Operating Cash Flow (TTM) | -12.94 M |
| Levered Free Cash Flow (TTM) | -11.59 M |
| Return on Assets (TTM) | -37.07% |
| Return on Equity (TTM) | -206.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Evaxion A/S | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients’ lives by providing innovative and targeted treatment options. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 23.07% |
| % Held by Institutions | 7.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Merck & Co., Inc. | 30 Sep 2025 | 1,214,126 |
| Beacon Capital Management, Llc | 30 Sep 2025 | 0 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (HC Wainwright & Co., 157.65%) | Buy |
| Median | 11.00 (77.13%) | |
| Low | 10.00 (Edward Jones, 61.03%) | Buy |
| Average | 12.33 (98.55%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 6.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Edward Jones | 30 Oct 2025 | 10.00 (61.03%) | Buy | 5.76 |
| HC Wainwright & Co. | 20 Oct 2025 | 16.00 (157.65%) | Buy | 7.09 |
| 25 Sep 2025 | 16.00 (157.65%) | Buy | 4.53 | |
| Lake Street | 20 Oct 2025 | 11.00 (77.13%) | Buy | 7.09 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |